Analyst Reco. Afya Limited

Equities

AFYA

KYG011251066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
17.35 ^USD	+4.39%		+8.23%	-20.88%

Mar. 15	Afya Q4 Adjusted Earnings, Revenue Rise; Issues 2024 Revenue Guidance	MT
Mar. 15	Afya Limited Provides Earnings Guidance for the FY2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22	Nov. 27	MT
Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating	22-11-22	MT
UBS Adjusts Afya Price Target to $18 From $21, Maintains Buy Rating	22-10-13	MT
Credit Suisse Upgrades Afya to Outperform from Neutral, Adjusts Price Target to $19 from $18	22-04-08	MT
UBS Adjusts Afya Price Target to $21 From $27, Maintains Buy Rating	22-03-07	MT
Goldman Sachs Adjusts Afya's Price Target to $19 From $29, Reiterates Buy Rating	22-02-15	MT
Afya : Sustainalytics ESG Risk Rating Is Publicly Available	21-09-28	BU
Afya : Sustainalytics ESG Risk Rating is Publicly Available	21-09-28	PU
AFYA : Morgan Stanley Downgrades Afya to Equalweight from Overweight, Adjusts Price Target to $28.50 from $32	21-07-21	MT
AFYA : UBS Upgrades Afya to Buy From Neutral, Citing Recent Sell-Off, Resiliency, Cash Generation; Price Target to $27 From $29.50	21-04-15	MT
AFYA : JPMorgan Upgrades Afya to Overweight From Neutral; Price Target is $34	21-02-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer